Sep 18, 2012, 08:40AM ISTCipla's FY13 topline growth guidance upgraded to 12-15% Cipla is looking to enter US markets solo. Bloomberg TV has learnt that the Cipla is keen to set up own front end facilities and is looking to independently market drugs, file ANDAs.The company, which is seeks to expand its international business, likes Teva model as growth route in the United States. Cipla believes that the strategy will grow despite its late entry. Cipla seeks to maintain leadership in India. It is evaluating strategic alliances and is looking to strengthen its joint ventures and partnerships. The company is also evaluating Turkey, Morocco, Nigeria and Brazil market.Cipla's FY13 topline growth guidance has been upgraded to 12-15% from 10%. The company expects 3-4 inhaler approvals in Europe by FY14.
Posts
No comments:
Post a Comment